About Formosa Pharmaceuticals

Company Introduction

Formosa Pharmaceuticals, a subsidiary of globally-recognized API and CDMO provider, Formosa Laboratories (TWSE 4746), is a late-preclinical and early-clinical stage biopharmaceutical company with focus in the indications of ophthalmology, oncology, and anti-infectives.

In August, 2017, Formosa Pharmaceuticals acquired Activus Pharmaceuticals (Funabashi, Japan), which afforded Formosa Pharmaceuticals a proprietary nanoparticle technology platform (APNT), and two late-stage preclinical assets in ophthalmology. Of these ophthalmology candidates, APP13007 has just begun Phase 3 clinical trials in the United States for inflammation and pain after ocular surgery.

Collaborating with global strategic partners, Formosa Pharmaceuticals has assembled a unique pipeline of diverse assets. Each opportunity has a different risk profile and enjoys a unique advantage with respect to the company’s resources, infrastructure, and network.

Formosa Pharmaceuticals continues to seek additional valued partnerships to complement its existing pipeline and platform technologies.

Formosa Pharmaceuticals is a preclinical and clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.

Scroll to Top